BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22453175)

  • 21. Regulation of proteasomes in prion disease.
    Zhu T; Hayat Khan S; Zhao D; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2014 Jul; 46(7):531-9. PubMed ID: 24829398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.
    Kristiansen M; Messenger MJ; Klöhn PC; Brandner S; Wadsworth JD; Collinge J; Tabrizi SJ
    J Biol Chem; 2005 Nov; 280(46):38851-61. PubMed ID: 16157591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases.
    Meneghetti E; Gasperini L; Virgilio T; Moda F; Tagliavini F; Benetti F; Legname G
    Mol Neurobiol; 2019 Sep; 56(9):6035-6045. PubMed ID: 30710214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A hypothesis on prion disorders: are infectious, inherited, and sporadic causes so distinct?
    Fornai F; Ferrucci M; Gesi M; Bandettini di Poggio A; Giorgi FS; Biagioni F; Paparelli A
    Brain Res Bull; 2006 Mar; 69(2):95-100. PubMed ID: 16533656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein misfolding cyclic amplification (PMCA): Current status and future directions.
    Saá P; Cervenakova L
    Virus Res; 2015 Sep; 207():47-61. PubMed ID: 25445341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prion protein oligomer and its neurotoxicity.
    Huang P; Lian F; Wen Y; Guo C; Lin D
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein.
    Piening N; Weber P; Giese A; Kretzschmar H
    Biochem Biophys Res Commun; 2005 Jan; 326(2):339-43. PubMed ID: 15582583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid cell-surface prion protein conversion revealed using a novel cell system.
    Goold R; Rabbanian S; Sutton L; Andre R; Arora P; Moonga J; Clarke AR; Schiavo G; Jat P; Collinge J; Tabrizi SJ
    Nat Commun; 2011; 2():281. PubMed ID: 21505437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells.
    Dron M; Dandoy-Dron F; Farooq Salamat MK; Laude H
    J Gen Virol; 2009 Aug; 90(Pt 8):2050-2060. PubMed ID: 19339478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.
    Nunziante M; Ackermann K; Dietrich K; Wolf H; Gädtke L; Gilch S; Vorberg I; Groschup M; Schätzl HM
    J Biol Chem; 2011 Sep; 286(39):33942-53. PubMed ID: 21835918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prion degradation pathways: Potential for therapeutic intervention.
    Goold R; McKinnon C; Tabrizi SJ
    Mol Cell Neurosci; 2015 May; 66(Pt A):12-20. PubMed ID: 25584786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular aspects of prion replication in vitro.
    Grassmann A; Wolf H; Hofmann J; Graham J; Vorberg I
    Viruses; 2013 Jan; 5(1):374-405. PubMed ID: 23340381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prion diseases and their biochemical mechanisms.
    Cobb NJ; Surewicz WK
    Biochemistry; 2009 Mar; 48(12):2574-85. PubMed ID: 19239250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into prion structure and toxicity.
    Harris DA; True HL
    Neuron; 2006 May; 50(3):353-7. PubMed ID: 16675391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
    Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
    J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural factors underlying the species barrier and susceptibility to infection in prion disease.
    Sweeting B; Khan MQ; Chakrabartty A; Pai EF
    Biochem Cell Biol; 2010 Apr; 88(2):195-202. PubMed ID: 20453922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. beta-sheet constitution of prion proteins.
    Ji HF; Zhang HY
    Trends Biochem Sci; 2010 Mar; 35(3):129-34. PubMed ID: 20060302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol.
    Wang X; Wang F; Sy MS; Ma J
    J Biol Chem; 2005 Jan; 280(1):317-25. PubMed ID: 15525638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.